The U.S. Food and Drug Administration (FDA) has introduced a new regulatory pathway aimed at accelerating the development and approval of personalized genetic therapies for rare diseases. The draft guidance, published Monday, outlines how individualized gene editing and RNA-based treatments can be brought to market when traditional large-scale clinical trials are not feasible.
Health Secretary Robert F. Kennedy Jr. addressed the new framework during a press conference, stating, “This framework aligns regulation with biology. For ultra-rare conditions, randomized controlled trials are often . . . just not feasible. Under the framework that we’re announcing today, one well-controlled clinical investigation supported by confirmatory evidence can support approval.”
The FDA’s move comes ahead of a bipartisan Senate hearing focused on rare disease therapy authorization processes. The new guidance draws attention to cases like Baby KJ, who last year received a personalized CRISPR treatment for an ultra-rare condition—an example highlighted in a November New England Journal of Medicine article by FDA Commissioner Marty Makary and Center for Biologics Evaluation and Research Director Vinay Prasad.
Industry analysts have noted that this approach could speed up the availability of gene therapies for patients with rare diseases who currently have few or no approved options. Previous FDA guidance did not address highly individualized therapies where limited patient populations make robust data collection challenging.
The proposed framework focuses on identifying the root genetic cause of a disease and developing drugs targeting that abnormality. It recommends using natural history data from untreated patients as control comparisons and demonstrating improvements in clinical outcomes alongside evidence confirming successful engagement with the intended biological target.
Harpreet Singh, chief medical officer at Precision for Medicine and former division director of Oncology at the FDA, remarked on the rapid release of this draft guidance: “It doesn’t really expand much on what the original [NEJM] article talked about, but . . . I think that’s most guidances.” She added that further industry feedback is needed to clarify certain points: “It’s on industry to respond to this and ask for more clarity.”
Singh also observed that cancer indications were absent from the document: “We are not seeing any nod or mention to any of the oncologic diseases, and I do think that this guidance certainly spans oncology,” she said.
Several companies are already expressing interest in utilizing the new pathway. Menlo Ventures cited it as supporting its investment in Aurora Therapeutics—a biotech company founded by CRISPR co-inventor Jennifer Doudna and Berkeley Professor Fyodor Urnova, both involved in Baby KJ’s treatment. Aurora aims to develop treatments for various gene variants causing phenylketonuria (PKU), especially those too rare to be addressed under current regulations.
Editor’s note: Heather McKenzie contributed reporting to this story.
